Al Marjan Island to feature Marriott International's second hospitality offering on its shores: W Al Marjan Island
31.8.2023 17:08:00 EEST | Business Wire | Press release
Marjan, the master developer of freehold properties in Ras Al Khaimah, today announced the launch of a W Hotel on Al Marjan Island on the back of a collaboration between Marriott International, Inc., and Dalands Holding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831309529/en/
Al Marjan Island to feature Marriott International's second hospitality offering on its shores: W Al Marjan Island (Photo: AETOSWire)
Slated for a grand opening early 2027, W Al Marjan Island is poised to achieve a dual distinction, not only as Marriott International’s second hospitality venture on the island, but also as W Hotel’s first property in Ras Al Khaimah, bringing the brand’s bold design, outstanding service and always-on programming to the northern emirate.
Destined to be located on Marjan’s flagship archipelago island, set against the picturesque backdrop of the Arabian Peninsula, and enclosed by the Yanas and Jais Mountains, the hotel will further elevate the appeal of this thriving leisure destination to globetrotters.
Featuring an inventory of 300 hotel rooms and suites with sweeping sea views, this magnificent property is anticipated to include signature spaces such as the Living Room, WET deck, W Lounge, AWAY Spa, and FIT fitness centre along with three restaurants and retail spaces.
Abdulla Al Abdouli, Chief Executive Officer, Marjan, said: “As Ras Al Khaimah rightfully solidifies its position on the global tourism landscape, we take pride in our significant contribution to enhancing its credibility and attractiveness among international investors. This commitment has led to a myriad of prestigious projects, as exemplified by the launch of W Al Marjan Island.”
"We are excited to work with Dalands Holding to bring W's invigorating energy and dynamic design to Al Marjan Island,” said Saahil Lalit, Vice President – Development, Middle East, Marriott International. “Ras Al Khaimah continues to be a sought-after leisure destination attracting global travellers to its idyllic beaches and attractions.”
Saurabh Gupta, CEO, Dalands Holding, said: "We believe this one-of-a-kind development will be immensely popular for its iconic design, luxurious accommodation and trendy culinary options. Like the other luxury hotels in our portfolio, we are developing W Al Marjan Island around the perceived needs of our future guests by curating exceptional offerings and unforgettable experiences.”
Endowed with white sandy beaches stretching over 7.8 km and a 23 km waterfront, an array of activities, and water sports, Al Marjan Island is reimagining luxurious waterfront living in Ras Al Khaimah.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831309529/en/
Contact information
Nivine William
nivine.william@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom